The Claim

In mice fed a high-fat diet, treatment with GW501516 is associated with increased plasma levels of β-hydroxybutyrate, suggesting enhanced hepatic fatty acid oxidation and ketogenesis.

Source: The PPARβ/δ activator GW501516 prevents the down-regulation of AMPK caused by a high-fat diet in liver and amplifies the PGC-1α-Lipin 1-PPARα pathway leading to increased fatty acid oxidation.

What the research says

Supports is higher

Support is ahead, but a single strong opposing study can change this.

Supports
12score
Challenges
0score

These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.

How it works
1 study reviewed
In plain English

In mice eating a high-fat diet, taking a drug called GW501516 seems to boost a substance in their blood that shows their liver is burning more fat for energy.

See the scientific wording

In mice on a high-fat diet, GW501516 treatment is associated with elevated plasma β-hydroxybutyrate levels, indicating increased hepatic fatty acid oxidation and ketogenesis.

What the research says

1 study

  1. Study: The PPARβ/δ activator GW501516 prevents the down-regulation of AMPK caused by a high-fat diet in liver and amplifies the PGC-1α-Lipin 1-PPARα pathway leading to increased fatty acid oxidation.

    The study gave GW501516 to mice on a high-fat diet and found their blood levels of a ketone (β-hydroxybutyrate) went up, which means their livers were burning more fat — just like the claim says.

Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies

Fit Body Science verdict — we translate health claims into clear verdicts backed by peer-reviewed research.

Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.